Growing evidence on AVM interventions contrasts with “horrible” ARUBA data

Recently, NeuroNews caught up with Christophe Cognard (Toulouse University Hospital, Toulouse, France) to discuss the current landscape of arteriovenous malformation (AVM) care. Cognard outlines the growing evidence and ongoing research that appear to contrast with seminal findings from ARUBA—a randomised trial in which the interventional treatment of AVMs produced “horrible” outcomes.